Search
Results: 3
Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases.
B-cell targeted therapies (BCTT) are now widely used in autoimmune rheumatic diseases, including SLE, antineutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis. Early studies suggested that rituximab did...
ADA2 deficiency complicated by EBV-driven lymphoproliferative disease.
Emily Staples, Ilenia Simeoni, Jonathan C Stephens, Hana Lango Allen, NIHR-BioResource, Penny Wright, E Graham Davies, Babak Javid, Effrossyni Gkrania-Klotsas, Michael Gattens, Helen Firth, Olga Shamardina, Sri VV Deevi, Matina Prapa, Ben Uttenthal, Dinakantha Kumararatne, James ED Thaventhiran
May 14, 2020
A 29-year old male with recurrent respiratory and skin infections, anaemia and neutropaenia during childhood required immunoglobulin replacement for antibody deficiency from age 16. He remained relatively well until age 28 when...
Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases.
Sonali Wijetilleka, David R Jayne, Chetan Mukhtyar, Aftab Ala, Philip D Bright, Hector Chinoy, Lorraine Harper, Majid A Kazmi, Sorena Kiani-Alikhan, Charles K Li, Siraj A Misbah, Louise Oni, Fiona E Price-Kuehne, Alan D Salama, Sarita Workman, David Wrench, Mohammed Yousuf Karim
Nov 27, 2019
OBJECTIVES: The association of B cell targeted therapies with development of hypogammaglobulinaemia and infection is increasingly recognized. Our aim was to develop consensus recommendations for immunoglobulin replacement...